Lecanemab Reduced Markers of Amyloid in Early Alzheimer Disease kxly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kxly.com Daily Mail and Mail on Sunday newspapers.
Although the novel tau aggregation inhibitor hydromethylthionine mesylate did not reach its coprimary endpoints, investigators insist there s more to the story ― especially with the control agent used.
For patients with early Alzheimer disease, lecanemab reduced markers of amyloid and resulted in moderately less decline in cognition and function at 18 months.